Advertisement

Clinical and Translational Oncology

, Volume 14, Issue 6, pp 486–488 | Cite as

Relevance of breast cancer subtypes for magnetic resonance imaging response monitoring during neoadjuvant chemotherapy

  • Cesar Gómez-RaposoEmail author
  • Mónica Andreu
  • Inés Suárez-García
  • M. Isabel Esteban
  • Mar Carballo
  • María F. Sereno-Moyano
  • José L. Vázquez Osorio
  • Javier Heras
  • Francisco Zambrana Tévar
  • Eva Pelayo
  • Miriam López-Gómez
  • Clara García de Santiago
  • María Merino Salvador
  • Enrique Casado
Brief Research Articles
  • 182 Downloads

Abstract

Changes in magnetic resonance imaging (MRI) during neoadjuvant chemotherapy (NAC) have been reported as predictive of pathology outcome in triple-negative and HER2-positive breast cancer. The purpose of our study was to evaluate the relevance of breast cancer subtype for MRI response in 24 women before and during NAC in our centre. Our results show that a reduction greater than 23% is associated with a pathological complete response (pCR) in Her-2-positive and ER-negative/Her2-negative breast cancer, and suggest a trend correlation between higher ADC values and pCR in these subtypes in comparison with ER-positive/Her2-negative breast cancers. Higher proliferating tumours respond better to chemotherapy and our study suggests that changes in MRI during NAC are predictive of pCR in these breast cancer subtypes.

Keywords

Breast cancer subtypes Predictive factors Neoadjuvant chemotherapy Magnetic resonance imaging 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wolmark N, Wang J, Mamounas E et al (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30:96–102PubMedCrossRefGoogle Scholar
  2. 2.
    Rastogi P, Anderson SJ, Bear HD et al (2008) Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 26:778–785PubMedCrossRefGoogle Scholar
  3. 3.
    Symmans WF, Peintinger F, Hatzis C et al (2007) Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414–4422PubMedCrossRefGoogle Scholar
  4. 4.
    Padhani AR, Hayes C, Assersohn L et al (2006) Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 239:361–374PubMedCrossRefGoogle Scholar
  5. 5.
    Loo CE, Straver ME, Rodenhuis S et al (2011) Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol 29:660–666PubMedCrossRefGoogle Scholar

Copyright information

© FESEO 2012

Authors and Affiliations

  • Cesar Gómez-Raposo
    • 1
    Email author
  • Mónica Andreu
    • 2
  • Inés Suárez-García
    • 3
  • M. Isabel Esteban
    • 4
  • Mar Carballo
    • 2
  • María F. Sereno-Moyano
    • 1
  • José L. Vázquez Osorio
    • 5
  • Javier Heras
    • 5
  • Francisco Zambrana Tévar
    • 1
  • Eva Pelayo
    • 5
  • Miriam López-Gómez
    • 1
  • Clara García de Santiago
    • 5
  • María Merino Salvador
    • 1
  • Enrique Casado
    • 1
  1. 1.Department of Medical OncologyHospital Universitario Infanta SofíaSan Sebastián de los Reyes, MadridSpain
  2. 2.Department of RadiologyHospital Universitario Infanta SofíaSan Sebastián de los Reyes, MadridSpain
  3. 3.Department of Internal MedicineHospital Universitario Infanta SofíaSan Sebastián de los Reyes, MadridSpain
  4. 4.Department of PathologyHospital Universitario Infanta SofíaSan Sebastián de los Reyes, MadridSpain
  5. 5.Department of GynecologyHospital Universitario Infanta SofíaSan Sebastián de los Reyes, MadridSpain

Personalised recommendations